top of page
Rechercher

FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer

Photo du rédacteur: nuaxia
nuaxia
il y a 1 jour
2 min de lecture

Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.


Biocon announced on 16 November 2026 that the US Food and Drug Administration had approved Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech's Perjeta, for HER2-positive breast cancer, marking the company's fifth oncology biosimilar approval in the United States.


Although the approval establishes a new regulatory milestone and a potential additional biosimilar treatment option, Biocon's global patent settlement with Genentech provides for the earliest licensed US commercial launch in the third quarter of 2028, meaning the decision does not constitute immediate market availability or evidence that Pebrilzo is clinically superior to the reference medicine.

Field

Content

Article Type

Approvals

Company

Biocon

Product Brand Name

Pebrilzo

Active Ingredient

Pertuzumab-qcay

Product Classification

Biosimilar

Reference Product

Perjeta

Reference Product Company

Genentech

Regulatory Authority

US Food and Drug Administration

Announcement Date

16 November 2026

Regulatory Decision

FDA biosimilar approval

Regulatory Market

United States

Therapeutic Area

Oncology

Cancer Type

Breast cancer

Molecular Subtype

HER2-positive

Therapeutic Target

HER2

Biocon US Oncology Biosimilar Portfolio Position

Fifth oncology biosimilar

Approval Status

Approved

US Commercial Launch Status

Not yet launched

Earliest Licensed US Launch

Third quarter of 2028

Launch Timing Basis

Global patent settlement with Genentech

Patent Settlement Counterparty

Genentech

Reference Medicine Comparison

Biosimilar to Perjeta

Clinical Superiority Established

No

Immediate US Commercial Availability

No

What Happened

The FDA approved Biocon's Pebrilzo as a biosimilar to pertuzumab reference medicine Perjeta.

Why It Matters

The approval expands the potential future range of biosimilar treatment options for HER2-positive breast cancer.

Regulatory Significance

Adds another FDA-approved oncology biosimilar to Biocon's portfolio.

Commercial Significance

Establishes regulatory readiness ahead of a planned US market entry permitted from the third quarter of 2028.

Access Implications

Future commercial entry may introduce additional competition in HER2-targeted oncology treatment.

Launch Clarification

FDA approval and commercial launch are separate milestones.

Patent Clarification

The reported patent settlement sets the earliest licensed US launch timing.

Key Takeaway

Pebrilzo has received FDA approval, but its earliest licensed US launch is scheduled for the third quarter of 2028.

What to Watch

Commercial launch preparations, patent settlement implementation, market access, pricing and adoption after launch.

Primary Source

Biocon

Primary Source URL

https://www.biocon.com/biocon-gets-u-s-fda-approval-for-pebrilzo-pertuzumab-qcay-injection-a-biosimilar-to-perjeta-expanding-its-oncology-portfolio/

Submitted Source

Business Standard

Submitted Source URL

https://www.business-standard.com/companies/news/biocon-secures-us-fda-approval-for-pebrilzo-its-fifth-cancer-biosimilar-126111600687_1.html

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

Commentaires

Noté 0 étoile sur 5.
Pas encore de note

Ajouter une note
bottom of page